GNMSF vs REGN: Which Stock is Better?
Side-by-side comparison of Genmab A/S and Regeneron Pharmaceuticals Inc in 2026
GNMSF
Genmab A/S
$281.75
REGN
Regeneron Pharmaceuticals Inc
$749.41
Key Metrics Comparison
| Metric | GNMSF | REGN | Winner |
|---|---|---|---|
| Market Cap | $17.75B | $79.35B | REGN |
| P/E Ratio | 18.32 | 18.08 | REGN |
| EPS (TTM) | $15.38 | $41.51 | REGN |
| Revenue Growth | 0.0% | 0.0% | GNMSF |
| Gross Margin | 93.6% | 44.6% | GNMSF |
Analyze GNMSF
Full quant analysis
Analyze REGN
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is GNMSF or REGN a better investment?
Comparing GNMSF and REGN: Genmab A/S has a market cap of $17.75B while Regeneron Pharmaceuticals Inc has $79.35B. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between GNMSF and REGN?
GNMSF (Genmab A/S) and REGN (Regeneron Pharmaceuticals Inc) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: GNMSF or REGN?
Based on P/E ratios, REGN trades at a lower multiple (18.1x vs 18.3x).
Which is growing faster: GNMSF or REGN?
GNMSF has higher revenue growth at 0.0% vs 0.0% for REGN.
Which company is more profitable: GNMSF or REGN?
Genmab A/S (GNMSF) has higher gross margins at 93.6% compared to 44.6% for REGN.
Which is the larger company: GNMSF or REGN?
Regeneron Pharmaceuticals Inc (REGN) is larger with a market cap of $79.35B compared to $17.75B for GNMSF.
Should I buy GNMSF or REGN in 2026?
Both GNMSF and REGN have investment merit. GNMSF trades at $281.75 while REGN trades at $749.41. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between GNMSF and REGN stock?
Key differences: Market Cap ($17.75B vs $79.35B), P/E Ratio (18.3x vs 18.1x), Revenue Growth (0.0% vs 0.0%), Gross Margin (93.6% vs 44.6%).